Home › Trial NCT05460195
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
- Trial IDNCT05460195
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorShanghai Chest Hospital
- Enrollment42
- Start date2022-01-01
- ConditionsNon-small Cell Lung Cancer · Minimal Residual Disease · Immunotherapy · Anti-angiogenesis
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.